Atlanta Consulting Group Advisors LLC Invests $1.11 Million in Sanofi (NASDAQ:SNY)

Atlanta Consulting Group Advisors LLC purchased a new position in shares of Sanofi (NASDAQ:SNY - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 19,272 shares of the company's stock, valued at approximately $1,111,000.

Several other institutional investors have also recently made changes to their positions in the company. POM Investment Strategies LLC purchased a new position in shares of Sanofi in the second quarter valued at approximately $25,000. Northwest Investment Counselors LLC purchased a new position in Sanofi in the 3rd quarter valued at approximately $29,000. Concord Wealth Partners grew its stake in shares of Sanofi by 157.8% in the third quarter. Concord Wealth Partners now owns 593 shares of the company's stock worth $34,000 after acquiring an additional 363 shares in the last quarter. Arrow Financial Corp acquired a new position in shares of Sanofi in the second quarter worth $35,000. Finally, Fortitude Family Office LLC increased its position in shares of Sanofi by 708.6% during the third quarter. Fortitude Family Office LLC now owns 752 shares of the company's stock worth $43,000 after acquiring an additional 659 shares during the period. Hedge funds and other institutional investors own 10.04% of the company's stock.

Sanofi Stock Performance

Shares of Sanofi stock traded up $0.15 on Friday, hitting $47.97. The stock had a trading volume of 3,651,145 shares, compared to its average volume of 2,104,559. The stock has a market cap of $121.74 billion, a price-to-earnings ratio of 24.47, a P/E/G ratio of 1.22 and a beta of 0.61. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. Sanofi has a 52-week low of $45.22 and a 52-week high of $58.97. The company's 50 day moving average price is $54.65 and its 200 day moving average price is $52.23.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its earnings results on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.22 by $1.35. The business had revenue of $13.44 billion for the quarter, compared to analyst estimates of $16.59 billion. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The company's revenue for the quarter was up 12.3% compared to the same quarter last year. During the same period last year, the firm posted $2.55 earnings per share. On average, research analysts anticipate that Sanofi will post 4.29 EPS for the current year.

Wall Street Analyst Weigh In

SNY has been the subject of a number of recent research reports. StockNews.com lowered Sanofi from a "strong-buy" rating to a "buy" rating in a report on Thursday, November 7th. Argus upped their price target on Sanofi from $55.00 to $60.00 and gave the company a "buy" rating in a report on Friday, July 26th. Finally, Citigroup upgraded shares of Sanofi to a "strong-buy" rating in a research note on Tuesday, September 17th. Two investment analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Sanofi presently has a consensus rating of "Moderate Buy" and an average target price of $57.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.